Research Topics
| D B CliffordSummaryAffiliation: Washington University School of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathyDavid B Clifford
Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
J Acquir Immune Defic Syndr 59:126-33. 2012..Effective treatment of HIV-associated distal sensory polyneuropathy remains a significant unmet therapeutic need...
Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in UgandaNoeline Nakasujja
Department of Public Health Sciences, Karolinska Institute, Stockholm, Sweden
BMC Psychiatry 10:44. 2010..Initiation of highly active antiretroviral therapy (HAART) may have an effect on the prevalence and the change over time of depression symptoms and cognitive impairment among HIV-positive individuals...
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathyD B Clifford
Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
Neurology 52:623-5. 1999..This is an improvement in prognosis compared with recent historic experience and correlated with HIV RNA viral load reductions. We conclude that current HIV therapy is important in improving the outlook of PML in the setting of HIV...- The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjectsDavid B Clifford
Washington University School of Medicine, St Louis, MO 63110, USA
AIDS 19:S64-71. 2005.... - Natalizumab and PML: a risky business?David B Clifford
Department of Neurology, Box 8111, 660 South Euclid Avenue, Saint Louis, MO 63110, USA
Gut 57:1347-9. 2008 - Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patientsD B Clifford
Washington University, St Louis, MO 63110, USA
Neurology 73:309-14. 2009..Interaction of the viruses is likely to be complicated and better understanding of the contributions of each virus will be necessary to make evidence-based therapeutic decisions... - CSF biomarkers of Alzheimer disease in HIV-associated neurologic diseaseD B Clifford
Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
Neurology 73:1982-7. 2009..CSF amyloid measurements in HAND have been reported to be similar to those in dementia of the Alzheimer type (DAT). Confirmatory evaluation of this finding in carefully evaluated subjects is needed... - Challenges for clinical trials to treat progressive multifocal leukoencephalopathyDavid B Clifford
Department of Neurology, Washington University School of Medicine, St Louis, Missouri 63110, USA
J Neurovirol 9:68-72. 2003..A controlled trial of therapy utilizing an international group of trial groups is proposed... - Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)David B Clifford
Washington University School of Medicine, St Louis, MO 63110, USA
HIV Clin Trials 10:343-55. 2009..Efavirenz (EFV) is an antiretroviral (ARV) drug associated with neuropsychological effects. Limited data describing the long-term impact of EFV-based regimens on neuropsychological performance over more than 3 years are available... - Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesDavid B Clifford
Department of Neurology, Washington University in St Louis, Saint Louis, MO 63110, USA
Lancet Neurol 9:438-46. 2010..Optimising the management of IRIS reactions will be needed to improve outcomes. Predictive markers for patients at risk for PML must be sought. It is crucial to monitor the risk incurred during use of natalizumab beyond 3 years... - Human immunodeficiency virus-associated dementiaD B Clifford
Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
Arch Neurol 57:321-4. 2000..Therapy for HIV in the central nervous system compartment remains potentially the most challenging therapeutic frontier for HIV control... - Neurologic consequences of hepatitis C and human immunodeficiency virus coinfectionDavid B Clifford
Washington University School of Medicine, St Louis, MI 63110, USA
J Neurovirol 11:67-71. 2005..Current evidence supports independent contributions of HCV and HIV to neurological impairment. Preliminary evidence suggests that coinfection-related impairment does not appear to accelerate HIV-1-associated cognitive disease... - Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritisDavid B Clifford
Department of Neurology, Washington University, St Louis, MO 63110, USA
Arch Neurol 68:1156-64. 2011..To describe the development of progressive multifocal leukoencephalopathy (PML) in patients with rheumatoid arthritis (RA) treated with rituximab... - AIDS dementiaDavid B Clifford
Department of Neurology, Washington University School of Medicine, Box 8111, 660 South Euclid Street, St Louis, MO 63110, USA
Med Clin North Am 86:537-50, vi. 2002..With current therapy, infection is never completely eradicated, and significant portions of toxicity seem mediated by indirect mechanisms that may continue even during antiretroviral therapy... - A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291J C McArthur
Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
Neurology 54:1080-8. 2000..To evaluate the safety and efficacy of recombinant human nerve growth factor (rhNGF) in HIV-associated sensory neuropathy (SN) within a multicenter, placebo-controlled, randomized trial (ACTG 291)... - Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathyG Schifitto
Department of Neurology, University of Rochester, NY 14642, USA
Neurology 57:1313-6. 2001..However, there was no improvement of neuropathy severity as assessed by neurologic examination, quantitative sensory testing, and epidermal nerve fiber density... - A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairmentD B Clifford
Department of Neurology, Washington University, St Louis, MO 63110, USA
Neurology 59:1568-73. 2002..It has neuroprotective properties in model systems for HIV-associated neurotoxicity and thus is a candidate for neuroprotective therapy in humans with HIV-associated CNS disease... - Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathyL Zhou
Department of Neurology, Johns Hopkins University, Baltimore, MD 21287 7609, USA
Neurology 68:2113-9. 2007..To demonstrate the relationship between epidermal nerve fiber density (ENFD) in the leg and the phenotype of HIV-associated distal sensory polyneuropathy (HIV-DSP) in a multicenter prospective study (ACTG A5117)... - Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control studyB M Ances
Department of Neurology, Washington University, St Louis, MO 63110, USA
Neurology 75:111-5. 2010..We evaluated the amyloid-binding agent (11)C-Pittsburgh compound B ((11)C-PiB), a biomarker for Alphabeta42 deposition, in cognitively unimpaired HIV+ (n = 10) participants and matched community controls without dementia (n = 20)... - Benefits and risks of stavudine therapy for HIV-associated neurologic complications in UgandaN Sacktor
Department of Neurology, Johns Hopkins Bayview Medical Center, Baltimore, MD 21224, USA
Neurology 72:165-70. 2009..Coformulated generic drugs, which include stavudine, are the most common regimens to treat HIV infection in Uganda and many other parts of Africa... - Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trialN Sacktor
Department of Neurology, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave, 301 Building, Suite 2100, Baltimore, MD 21224, USA
Neurology 77:1135-42. 2011..We conducted a study of minocycline to assess its safety, tolerability, and efficacy for the treatment of HIV-associated cognitive impairment... - Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathyM Polydefkis
Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
Neurology 58:115-9. 2002..To explore the relationship between intraepidermal nerve fiber (IENF) density in HIV-associated sensory neuropathy (HIV-SN) to measurements of neuropathy severity and progression of HIV disease... - A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairmentG Schifitto
Department of Neurology, Movement and Inherited Neurologic Disorders, Clinical Trials Coordination Center, 1351 Mount Hope Avenue, Suite 223, Rochester, NY 14620, USA
Neurology 69:1314-21. 2007..This rationale has led to the design and implementation of this Selegiline Transdermal System (STS) study with the primary aims of assessing safety and tolerability of STS as well as improvement in cognitive performance... - Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathyM A Lima
Department of Neurology, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, MA 02215, USA
J Neurol Neurosurg Psychiatry 81:1288-91. 2010..In absence of a specific treatment, immunotherapies aiming at boosting the cellular immune response against JCV may improve the prognosis of PML... - Effects of fructose-1,6-bisphosphate on morphological and functional neuronal integrity in rat hippocampal slices during energy deprivationY Izumi
Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63310, USA
Neuroscience 116:465-75. 2003.... - Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosisJagannadha R Avasarala
Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
Mult Scler 9:59-62. 2003..It is suggested that more stringent cardiac monitoring guidelines than current Food and Drug Administration (FDA) recommendations be used to avert potential cardiac complications in SPMS patients on Mitoxantrone... - Neurological evaluation of untreated human immunodeficiency virus infected adults in EthiopiaDavid B Clifford
Department of Neurology, Washington University in St Louis, St Louis, Missouri 63110, USA
J Neurovirol 13:67-72. 2007..The unanticipated minor evidence of HIV-associated neurocognitive and peripheral nerve deficits in this untreated HIV-positive population invite further investigation... - Role of metabolic syndrome components in HIV-associated sensory neuropathyBeau M Ances
Department of Neurology, Washington University, St Louis, 660 South Euclid Avenue, Box 8111, St Louis, MO 63110, USA
AIDS 23:2317-22. 2009..We examined whether MetS or its components predispose individuals to HIV-associated sensory neuropathy (HIV-SN)... - HIV-associated neurocognitive disease continues in the antiretroviral eraDavid B Clifford
Washington University School of Medicine, Saint Louis, MO, USA
Top HIV Med 16:94-8. 2008..This article summarizes a presentation on HIV-associated neurocognitive disorder made by David B. Clifford, MD, at an International AIDS Society-USA Continuing Medical Education course in New York in October 2007... - Bk virus: a clinical reviewM D Reploeg
Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
Clin Infect Dis 33:191-202. 2001.... - Immune reconstitution inflammatory syndrome in natalizumab-associated PMLI L Tan
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
Neurology 77:1061-7. 2011..To study the outcome of patients with multiple sclerosis (MS) and with natalizumab-associated progressive multifocal leukoencephalopathy (PML) and immune reconstitution inflammatory syndrome (IRIS)... - Atypical PML leading to a diagnosis of common variable immunodeficiencyMichael D Snyder
Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA
Neurology 64:1661. 2005 - HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapiesBeau M Ances
Department of Neurology, University of Washington, St Louis, MO 63130, USA
Curr Neurol Neurosci Rep 8:455-61. 2008..Because viral control generally has been successful without eliminating cognitive dysfunction, further clinical studies that assess adjunctive neuroprotective drugs are likely to be required... - Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performanceChristina M Marra
Department of Neurology, University of Washington School of Medicine, Seattle, USA
AIDS 23:1359-66. 2009..To determine whether antiretroviral regimens with good central nervous system (CNS) penetration control HIV in cerebrospinal fluid (CSF) and improve cognition... - HIV-associated cognitive impairment in sub-Saharan Africa--the potential effect of clade diversityNed Sacktor
Department of Neurology, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD 21224, USA
Nat Clin Pract Neurol 3:436-43. 2007..Further studies are needed to determine the true prevalence of HIV dementia in sub-Saharan Africa and to establish whether specific clade subtypes might influence the presentation of neurological complications... - Genotyping of Toxoplasma gondii strains from immunocompromised patients reveals high prevalence of type I strainsA Khan
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA
J Clin Microbiol 43:5881-7. 2005..The multiplex nested PCR analysis described here will be useful for analyzing the contribution of parasite genotype to toxoplasmosis... - Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathyMarco A Lima
Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
J Virol 81:3361-8. 2007..Immunotherapies aiming at increasing the cellular immune response against JCV may be valuable in the treatment of HIV+ individuals with PML... - Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individualsDavid B Clifford
Washington University School of Medicine, Neurology Department, St. Louis, Missouri 63110, USA
Ann Intern Med 143:714-21. 2005..Improvement in neuropsychological performance was comparable in patients who were receiving efavirenz and those who were not... - Clinical validation of the NeuroScreenRonald J Ellis
Department of Neurosciences, UCSD AntiViral Research Center and HIV Neurobehavioral Research Center, University of California, San Diego, California 92103, USA
J Neurovirol 11:503-11. 2005..However, because it yields substantial numbers of false positives and negatives, the NeuroScreen may be less useful in evaluating individual patients... - Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathyTarek A Yousry
Institute of Neurology, Queen Square, London
N Engl J Med 354:924-33. 2006..9 months. The risk associated with longer treatment is not known... - Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090Scott R Evans
Harvard School of Public Health, Boston, Massachusetts, USA
HIV Clin Trials 8:437-46. 2007..To assess the long-term safety (primary aim) and efficacy (secondary aim) of the MAO-B inhibitor Selegiline Transdermal System (STS) for the treatment of HIV-associated cognitive impairment... - Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoringLudwig Kappos
University Hospital, Basel, Switzerland
Lancet Neurol 6:431-41. 2007..Maintaining clinical vigilance allows for early suspension of natalizumab in potential cases of PML, thereby increasing the opportunity for immune reconstitution, which may improve prognosis if PML is confirmed... - Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysisAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Lazio Region, Rome, Italy
AIDS 22:1759-67. 2008..To establish the effectiveness of cidofovir for AIDS-related progressive multifocal leukoencephalopathy (PML) in patients concomitantly receiving combination antiretroviral therapy... - Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patientsLucette A Cysique
St Vincent s Hospital Clinical School, University of New South Wales, Darlinghurst, Sydney, Australia
J Acquir Immune Defic Syndr 39:426-9. 2005.... - Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group studyTodd Hulgan
Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
AIDS 19:1341-9. 2005..The objective of this study was to determine if NRTI-associated peripheral neuropathy is associated with European mitochondrial haplogroups... - The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous systemScott L Letendre
University of California, 150 W Washington St, San Diego, CA 92103, USA
J Neuroimmune Pharmacol 2:120-7. 2007..Some of these drugs, such as serotonin reuptake inhibitors (SRIs) and HMG-CoA reductase inhibitors (statins), may do so by reducing HIV replication in the CNS and are already widely used by HIV-infected individuals... - Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group studyAlison A Motsinger
Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
Pharmacogenet Genomics 16:837-45. 2006..We examined whether long-term responses to efavirenz, and/or plasma efavirenz exposure, are better predicted by multilocus genetic interactions than by individual polymorphisms... - Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group studyTodd Hulgan
Vanderbilt University School of Medicine, Nashville, TN 37203, USA
J Acquir Immune Defic Syndr 42:450-4. 2006..Mitochondria play a central role in regulating oxidant stress. We explored the relationships between oxidant stress and NRTI-induced peripheral neuropathy... - Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapyAsha R Kallianpur
Department of Medicine, Divisions of General Internal Medicine and Public Health, Nashville, TN, USA
AIDS 20:1503-13. 2006..Since iron deficiency is associated with some types of PN, and iron is essential for mitochondrial function, we tested the hypothesis that hemochromatosis (HFE) gene mutations influence susceptibility to NRTI-induced PN... - Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group StudyDavid W Haas
Vanderbilt University School of Medicine, Nashville, TN 37203, USA
J Infect Dis 192:1931-42. 2005..Nelfinavir is a substrate for P-glycoprotein, which is encoded by MDR1. The present study examined associations between genetic variants and long-term responses to treatment... - Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group studyDavid W Haas
Program for Human Genetics, Vanderbilt University School of Medicine, 345 24th Avenue North, Nashville, TN 37203, USA
AIDS 18:2391-400. 2004..Efavirenz is metabolized by cytochrome P4502B6 (CYP2B6). We investigated whether polymorphisms in CYP2B6, CYP3A4, CYP3A5, and MDR1 were associated with efavirenz central nervous system side effects and pharmacokinetics... - The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminologyPaola Cinque
Clinic of Infectious Diseases, San Raffaele Hospital, Milano, Italy
J Neurovirol 9:88-92. 2003..A standard patient classification would be helpful for clinical management of PML patients, for their inclusion in clinical studies, and also will increase our current knowledge of PML and its evolution in relation with HAART... - Part 2: history of 20th century neurology: decade by decadeKenneth Tyler
Ann Neurol 53:S27-45. 2003